US Biotest, Inc.
16
0
0
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 70/100
37.5%
6 terminated/withdrawn out of 16 trials
62.5%
-24.0% vs industry average
0%
0 trials in Phase 3/4
110%
11 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (16)
Trial of NanoPac Intratumoral Injection in Lung Cancer
Role: collaborator
Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma
Role: collaborator
Safety and Efficacy of USB002 for Respiratory Distress Due to COVID-19
Role: lead
Evaluation of NanoDoce® in Participants With Urothelial Carcinoma
Role: collaborator
Trial of NanoPac Focal Therapy for Prostate Cancer
Role: collaborator
Study of Topical SOR007 Ointment for Cutaneous Metastases
Role: collaborator
Intracystic Injection of NanoPac® in Subjects With Mucinous Cystic Pancreatic Neoplasms
Role: collaborator
Phase II Study of Intraperitoneal NanoPac® in Patients With Ovarian Cancer
Role: collaborator
Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma
Role: collaborator
Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer
Role: collaborator
Study of SOR007 Ointment for Actinic Keratosis
Role: collaborator
Study of the Safety of USB005 in Healthy Volunteers
Role: lead
Trial to Assess the Potency of SOR007 Ointment in a Psoriasis Plaque Test
Role: collaborator
Study of SOR007 Ointment for Cervical Intraepithelial Neoplasia (CIN)
Role: collaborator
Safety and Efficacy Study of DSC127 in Treating Subjects With Diabetic Ulcers
Role: lead
Safety Study of TXA127 to Elevate CD4+ T-Lymphocyte Counts in HIV-Infected Patients on Stable HAART Therapy
Role: lead
All 16 trials loaded